These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 25736944)

  • 1. Physical compatibility of cisatracurium with selected drugs during simulated Y-site administration.
    Foushee JA; Fox LM; Gormley LR; Lineberger MS
    Am J Health Syst Pharm; 2015 Mar; 72(6):483-6. PubMed ID: 25736944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration.
    Trissel LA; Martinez JF; Gilbert DL
    Am J Health Syst Pharm; 1997 Aug; 54(15):1735-41. PubMed ID: 9262747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Y-site Physical Compatibility of Beta-blocker Infusions with Intensive Care Unit Admixtures.
    Foushee JA; Meredith P; Fox LM; Grace E
    Int J Pharm Compd; 2016; 20(4):328-332. PubMed ID: 28333677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Y-site physical compatibility of hydrocortisone continuous infusions with admixtures used in critically ill patients.
    Foushee JA; Meredith P; Fox LM; Wilder AG
    Am J Health Syst Pharm; 2020 Jul; 77(14):1144-1148. PubMed ID: 32537625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Physical and chemical compatibility of drotrecogin alfa (activated) with 34 drugs during simulated Y-site administration.
    Mann HJ; Demmon SL; Boelk DA; Payne CA; Effron MB; Rajagopalan N; Williams MD; Beck GM; Gopalrathnam G
    Am J Health Syst Pharm; 2004 Dec; 61(24):2664-71. PubMed ID: 15646701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stability of cisatracurium besylate in vials, syringes, and infusion admixtures.
    Xu QA; Zhang YP; Trissel LA; Gilbert DL; Martinez JF; Fox JL
    Am J Health Syst Pharm; 1998 May; 55(10):1037-41. PubMed ID: 9606456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physical compatibility of alprostadil with selected drugs commonly used in the neonatal intensive care units.
    De Basagoiti A; Katsumiti A; Abascal S; Bustinza A; López-Giménez LR; Pascual P; De Miguel M; Campino A
    Eur J Pediatr; 2021 Apr; 180(4):1169-1176. PubMed ID: 33128625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simulated Y-site compatibility of atosiban acetate with selected intravenous drugs.
    Jiménez-Lozano I; Larrosa-García M; Boix-Montañés A; Bautista SC; Poy MJC
    Eur J Obstet Gynecol Reprod Biol; 2022 Aug; 275():106-109. PubMed ID: 35779331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Turbidimetric assessment of the compatibility of taxol with selected other drugs during simulated Y-site injection.
    Trissel LA; Bready BB
    Am J Hosp Pharm; 1992 Jul; 49(7):1716-9. PubMed ID: 1352424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Physical compatibility of ceftolozane-tazobactam with selected i.v. drugs during simulated Y-site administration.
    Thabit AK; Hamada Y; Nicolau DP
    Am J Health Syst Pharm; 2017 Jan; 74(1):e47-e54. PubMed ID: 28007721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Physical and chemical stability of palonosetron hydrochloride with five opiate agonists during simulated Y-site administration.
    Trissel LA; Trusley C; Ben M; Kupiec TC
    Am J Health Syst Pharm; 2007 Jun; 64(11):1209-13. PubMed ID: 17519464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Physical compatibility of Normosol-R with critical care medications used in patients with COVID-19 during simulated Y-site administration.
    Holyk AA; Lindner AH; Lindner SE; Shippert BW
    Am J Health Syst Pharm; 2022 Jan; 79(1):e27-e33. PubMed ID: 34390244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physical compatibility of tedizolid phosphate with selected i.v. drugs during simulated Y-site administration.
    Ghazi I; Hamada Y; Nicolau DP
    Am J Health Syst Pharm; 2016 Nov; 73(21):1769-1776. PubMed ID: 27769972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection.
    Trissel LA; Martinez JF
    Am J Hosp Pharm; 1994 Feb; 51(4):495-9. PubMed ID: 8017415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Physical and chemical stability of palonosetron hydrochloride with five common parenteral drugs during simulated Y-site administration.
    Kupie TC; Trusley C; Ben M; Trissel LA
    Am J Health Syst Pharm; 2008 Sep; 65(18):1735-59. PubMed ID: 18769000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration.
    Asempa TE; Avery LM; Kidd JM; Kuti JL; Nicolau DP
    Am J Health Syst Pharm; 2018 Jul; 75(14):1048-1056. PubMed ID: 29895521
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nefopam hydrochloride compatibility and stability with selected proton pump inhibitors in bionolyte G5 injection for intravenous infusion.
    Kambia NK; Luyckx M; Dine T; Dupin-Spriet T; Gressier B; Brunet C
    J Clin Pharm Ther; 2009 Feb; 34(1):25-31. PubMed ID: 19125900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Compatibility and stability of palonosetron hydrochloride with four neruomuscular blocking agents during simulated y-site administration.
    Trusley C; Ben M; Kupiec TC; Trissel LA
    Int J Pharm Compd; 2008; 12(2):156-60. PubMed ID: 23969608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The compatibility of nicardipine hydrochloride injection with various ICU medications during simulated Y-site injection.
    Halpern NA; Colucci RD; Alicea M; Greenstein R
    Int J Clin Pharmacol Ther Toxicol; 1989 May; 27(5):250-4. PubMed ID: 2737791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration.
    Singh BN; Dedhiya MG; DiNunzio J; Chan P; Kupiec TC; Trissel LA; Laudano JB
    Am J Health Syst Pharm; 2011 Nov; 68(22):2163-9. PubMed ID: 22058102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.